

# MONOCLONAL ANTIBODIES

## and Fc fusion proteins for therapeutic use

### DISTRIBUTION OF INTERNATIONAL NONPROPRIETARY NAMES BY INDICATION

SOLID TUMORS	
Lung cancer	bevacizumab nivolumab necitumumab atezolizumab
Colorectal cancer	bevacizumab cetuximab panitumumab afibercept
Bladder cancer	atezolizumab
Breast cancer	trastuzumab bevacizumab pertuzumab trastuzumab entansine
Gastric cancer	trastuzumab ramucirumab
Head and neck cancer	cetuximab
Ovarian cancer	bevacizumab
Fallopian tube cancer	bevacizumab
Cervical cancer	bevacizumab
Kidney cancer	bevacizumab nivolumab
Melanoma	ipilimumab nivolumab pembrolizumab
Neuroblastoma	dinutuximab
Malignant ascites	catumaxomab
Bone metastasis	denosumab
Soft tissue sarcoma	olaratumab
Merkel cell carcinoma	avelumab
HAEMATOLOGIC DISEASES	
Hodgkin's Lymphoma	brentuximab vedotin nivolumab
Non-Hodgkin's Lymphomas	rituximab ibrutumomab tiuxetan brentuximab vedotin inotuzumab ozogamicine obinutuzumab
Chronic lymphocytic leukaemia	rituximab alemtuzumab ofatumumab obinutuzumab
Acute lymphocytic leukaemia	blinatumomab inotuzumab ozogamicine
Acute myeloid leukaemia	gemtuzumab ozogamicine
Multiple myeloma	daratumumab elotuzumab
Paroxysmal nocturnal haemoglobinuria	eculizumab
IMMUNOLOGY	
Systemic lupus erythematosus	belimumab
Castleman's disease	siltuximab

RHUMATOLOGY	
Rheumatoid arthritis	etanercept infliximab adalimumab rituximab abatacept tocilizumab certolizumab pegol golimumab
Psoriatic arthritis	etanercept adalimumab infliximab golimumab ustekinumab certolizumab pegol secukinumab
Ankylosing spondylitis	infliximab etanercept adalimumab golimumab certolizumab pegol secukinumab
Juvenile arthritis	etanercept adalimumab abatacept tocilizumab canakinumab
Gouty arthritis	canakinumab
Osteoporosis	denosumab
GASTROENTEROLOGY	
Crohn's disease	infliximab adalimumab vedolizumab ustekinumab
Ulcerative colitis	infliximab adalimumab golimumab vedolizumab
NEUROLOGY	
Multiple sclerosis	natalizumab alemtuzumab daclizumab
DERMATOLOGY	
Psoriasis	etanercept infliximab adalimumab ustekinumab secukinumab ixekizumab
Chronic spontaneous urticaria	omalizumab

PNEUMOLOGY	
Allergic asthma	omalizumab
Severe eosinophilic asthma	mepolizumab reslizumab
TRANSPLANTATION	
Transplant rejection	basiliximab belatacept
Graft versus host disease	inolimomab
OPHTHALMOLOGY	
Age related macular degeneration	ranibizumab afibercept bevacizumab
Macular edema	ranibizumab afibercept
Myopic choroidal neovascularization	ranibizumab afibercept
HAEMOSTASIS AND THROMBOSIS	
Haemophilia A	efmoroctocog $\alpha$
Haemophilia B	eftrenonacog $\alpha$
Reversal of dabigatran	idarucizumab
Idiopathic thrombocytopenic purpura	romiplostim
Unstable angina	
Percutaneous coronary intervention	abciximab
ENDOCRINOLOGY AND METABOLISM	
Type 2 diabetes	dulaglutide
INFECTIOUS DISEASES	
Prevention of respiratory syncytial virus infection	palivizumab
Anthrax infection	raxibacumab oblitoxaximab
Prevention of <i>Clostridium difficile</i> infections	bezlotoxumab
GENETIC DISEASES	
Cryopyrinopathies	canakinumab
Atypical hemolytic uremic syndrome	eculizumab
Familial hypercholesterolemias	evolocumab alirocumab